Genmab — April 2017
-
Jeg kan ikke lige se noget med de 67 dage i linket?
-
Det kan du i dette link, hvis du scroller til bunds http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001595.jsp&mid=WC0b01ac0580b18a3d
-
-
og hvad der foregår i de 67 dage fremgår af slide 16/21
-
Det kan vel godt være at beslutningen træffes efter mandag - men vi må være lige op over!
-
Tak Bulder og flottenschmecker.
-
ja, jeg har ikke været i stand til at trænge igennem til noget materiale omkring kommissionens arbejde på det her området. Det virker ret "black box" agtigt
-
hvis vi kan tage udgangspunkt i imbruvicas Q1 performance - så er det her muligvis en af de helt store dage i GENs historie. Med EU approval kan omsætningen af dara virkelige begynde at spadsere!
-
approval!
-
-
Company Announcement
DARZALEX approved in Europe in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone in patients who have received at least one prior therapy
Genmab to receive milestone payments totaling USD 48 million from Janssen upon the first sale of DARZALEX in the newly approved indications -
milestone!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind